Acetylcysteine Augmentation in Treatment of Refractory Obsessive-Compulsive Disorder
Phase 2
- Conditions
- Obsessive-compulsive disorder.Obsessive-compulsive disorder
- Registration Number
- IRCT201103243930N4
- Lead Sponsor
- Vice chancellor for research, Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Inclusion Criteria are: DSM-IV diagnosis of OCD; symptoms of at least 1 year duration, moderate to severe OCD symptoms (Y-BOCS > 16), and failure of an adequate trial of an SSRI.
Exclusion Criteria are: primary diagnosis of a psychotic disorder, active substance abuse or dependence, unstable medical condition, prior exposure to N-Acetylcysteine, pregnancy, breastfeeding, or intent to become pregnant during study, evidence of active liver disease, seizure disorder, and active suicidal ideation.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Yale-Brown Obsessive-Compulsive Scale. Timepoint: every 2 weeks for 10 weeks. Method of measurement: Interview.
- Secondary Outcome Measures
Name Time Method Clinical Global Impression. Timepoint: every 2 weeks for 10 weeks. Method of measurement: Self-report.